Medicare 2024 Diabetes Prescribing Aid
Date: 05/28/24
2024 Diabetes Prescribing Aid MAPD: D-SNP, C-SNP, & PPO
Benefits subject to evidence of coverage. Information on copays/cost sharing, deductibles, and gap coverage can be found in the Summary of Benefits on our website:
H0351, H5590: Wellcare By Allwell H8553: Wellcare
2024 Preferred Insulin Products | |
Fast Acting |
|
Short Acting |
|
Intermediate Acting |
|
Long Actiing |
|
Combinations | Insulins
Insulin + GLP-1 receptor agonist
|
|
For more than 20 years, Wellcare has ofered a range of Medicare products, which ofer afordable coverage beyond OriginalMedicare. Beginning Jan. 1, 2022, our afliated Medicare brands, including Allwell, transitioned to a newly refreshed and unifid Wellcare brand. If you have any questions, please contact Provider Relations.
2024 Preferred Anti-Diabetic (non-insulin) Medications |
GENERIC ORAL ANTI-DIABETIC MEDICATIONS:
|
|
DPP-4 INHIBITOR:
DPP-4 COMBINATIONS:
|
|
SGLT-2 INHIBITOR:
SGLT-2 INHIBITOR COMBINATION:
|
|
GLP-1 AGONIST:
|
|
2024 Preferred Blood Glucose Meters and Strips One Touch Verio Reflect or Verio Flex meter and One Touch Verio test strips; One Touch Ultra 2meter and One Touch Ultra test strips |
Test Strip Quantity Limits:
|
Note: Continuous Glucose Monitoring (CGM) systems require Prior Authorization(PA). FreeStyle Libre or DexCom are preferred/PA required. PA criteria: DM diagnosis, insulin-treated, has had more than one level 2 hypoglycemic event (BG < 54 mg/dL) that persists despite more than one attempt toadjust medications and/or modify diabetes treatment plan OR one level 3 hypoglycemic event (BG< 54 mg/dL) characterized by altered mental and/or physical state requiring third-party assistancefor treatment, seen by provider in last six months, and will have follow-up appointments every sixmonths to document adherence to both the CGM regimen and diabetes treatment plan. The CoverageDetermination form for PA request is available on our website. |